- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
J Hepatol. 2016 May 19. pii: S0168-8278(16)30202-1. doi: 10.1016/j.jhep.2016.05.016. [Epub ahead of print]
Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B.Lok AS1, Pan CQ2, Han SB3, Trinh HN4, Fessel WJ5, Rodell T6, Massetto B7, Lin L7, Gaggar A7, Subramanian GM7, McHutchison JG7, Ferrari C8, Lee H9, Gordon SC10, Gane EJ11.
Author information
- 1Division of Gastroenterology and Hepatology, University of Michigan Health System, Ann Arbor, MI, USA. Electronic address: [email protected].
- 2Department of Medicine, New York University Langone Medical Center, New York University School of Medicine, NY, USA.
- 3Department of Medicine, Ronald Reagan UCLA Medical Center, Los Angeles, CA, USA.
- 4San Jose Gastroenterology, San Jose, CA, USA.
- 5Department of Medicine, Kaiser Permanente, San Francisco, CA, USA.
- 6GlobeImmune, Louisville, CO, USA.
- 7Gilead Sciences, Inc., Foster City, CA, USA.
- 8Department of Infectious Diseases,]University of Parma, Italy.
- 9Division of Gastroenterology and Hepatology, Tufts Medical Center, Boston, MA, USA.
- 10Division of Gastroenterology, Henry Ford Hospital, Detroit, MI, USA.
- 11Auckland City Hospital, Auckland, New Zealand.
AbstractBACKGROUND & AIMS: GS-4774 is a heat-inactivated, yeast-based, T-cell vaccine designed to elicit hepatitis B virus (HBV)-specific T-cell responses. We evaluated the safety, tolerability and efficacy of GS-4774 in patients with chronic HBV infection.
METHODS: In this phase II study, 178 patients with chronic HBV infection and no cirrhosis who were virally suppressed on an oral antiviral (OAV) for ⩾1 year were randomized (1:2:2:2) to continue OAV alone or receive OAV plus GS-4774 2, 10, or 40 yeast units (YU) subcutaneously every 4 weeks until week 20. OAV was continued for the remainder of the study. Efficacy was measured by decline in serum hepatitis B surface antigen (HBsAg) from baseline to week 24.
RESULTS: Baseline characteristics were similar across groups (mean age, 45-50 years; male, 62-74%; Asian, 68-80%; hepatitis B e antigen (HBeAg)-positive, 24-26%; mean HBsAg, 2.5-3.1 log10 IU/ml). There were no significant differences between groups in mean HBsAg declines from baseline to week 24 or 48. Five HBeAg-positive patients receiving GS-4774 experienced HBeAg loss vs. none in the control group. Three GS-4774 40 YU-treated patients had HBsAg declines ⩾0.5 log10 IU/ml, but no patient experienced loss of serum HBsAg. No virologic breakthrough occurred. Injection site reactions were the most frequent adverse event (AE), and there were no treatment discontinuations.
CONCLUSIONS: GS-4774 was well tolerated, but did not provide significant reductions in serum HBsAg in virally suppressed patients with chronic hepatitis B. Efficacy of GS-4774 in treatment naïve patients remains to be determined.
LAY SUMMARY: GS-4774 is a therapeutic vaccine designed to improve the immune response against hepatitis B virus (HBV) in patients who already have chronic infection with HBV. In this study, GS-4774 was safe and well tolerated in patients with chronic HBV infection receiving oral antiviral therapy, but did not result in a clinical benefit. Combination approaches with other agents, and evaluation in other populations of patients with HBV are ongoing to determine if GS-4774 might have a therapeutic benefit.
Copyright © 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
KEYWORDS: GS-4774; Hepatitis B e antigen; Hepatitis B surface antigen; Hepatitis B virus; Nucleoside/nucleotide analogue; Phase II
PMID:27210427 [PubMed - as supplied by publisher] |
|